21.06.2008 at 08:00
- Category:
Cancer and Oncology
The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.
"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."
Copyright 2008, Oncology Business Week via NewsRx.com
